Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Literature
1.
Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, and Halsey C (2016) Drug reactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. 78:1093–1096
2.
Aur R, Hustu O, Simone J (1976) Leukoencephalopathy (LEP) in children with acute lymphocytic leukemia (ALL) receiving preventative central nervous system (CNS) therapy. Proc Am Ass Cancer Res 17:97
3.
Krull K, Cheung YT, Liu W et al (2016) Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 34:2644–2653CrossRefPubMed
4.
Duffner PK, Armstrong FD, Chen L et al (2014) Neurocognative and neuroradiologic central nervous system late effects in children treated on pediatric oncology group (POG) P9605 (standard risk) and P9201 (lesser risk)acute lymphoblastic leukemia protocols (ACCL0131):a methotrexate consequence? A report from the children’s oncology group. J Pediatr Hematol/Oncol 36:8–15CrossRef
5.
Bonda-Shkedi E, Weyl Ben Arush M, Chaim Kaplinsky C et al (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated forosteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study J Pediatr Hematol Oncol 35:271–275CrossRefPubMed
Metadata
Title
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?
Author
Ian Joseph Cohen
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3234-0

Other articles of this Issue 2/2017

Cancer Chemotherapy and Pharmacology 2/2017 Go to the issue

Original Article

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

Review Article

Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues

Original Article

Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice

Original Article

Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205

Review Article

Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells

Original Article

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits